Salicylic acid [69-72-7]
Cat# HY-B0167-10g
Size : 10g
Brand : MedChemExpress
Salicylic acid (2-Hydroxybenzoic acid) inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation.
For research use only. We do not sell to patients.
Salicylic acid Chemical Structure
CAS No. : 69-72-7
This product is a controlled substance and not for sale in your territory.
Based on 8 publication(s) in Google Scholar
Other Forms of Salicylic acid:
- Sodium Salicylate In-stock
- Salicylic acid-d6 In-stock
- Salicylic acid-13C6 In-stock
- Salicylic acid (Standard) Get quote
View All COX Isoform Specific Products:
Description |
Salicylic acid (2-Hydroxybenzoic acid) inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation[1]. |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||
In Vitro |
Salicylic acid is an effective inhibitor of COX-2 activity at concentrations far below those required to inhibit NF-κB (20 mg/mL) activation. Salicylic acid inhibits prostaglandin E2 release when add together with interleukin 1β for 24 hr with an IC50 value of 5 μg/mL, an effect that is independent of NF-κB activation or COX-2 transcription or translation. Salicylic acid acutely (30 min) also causes a concentration-dependent inhibition of COX-2 activity measured in the presence of 0, 1, or 10 μM exogenous arachidonic acid. In contrast, when exogenous arachidonic acid is increased to 30 μM, Salicylic acid is a very weak inhibitor of COX-2 activity with an IC50 of >100 μg/mL. When added together with IL-1β for 24 hr, Salicylic acid causes a concentration-dependent inhibition of PGE2 release with an apparent IC50 value of approximately 5 μg/mL. The ability of Salicylic acid to directly inhibit COX-2 activity in A549 cells is tested after a 30-min exposure period, followed by the addition of different concentrations of exogenous arachidonic acid (1, 10, and 30 μM). Salicylic acid causes a concentration-dependent inhibition of COX-2 activity in the absence of added arachidonic acid or in the presence of 1 or 10 μM exogenous substrate with an apparent IC50 value of approximately 5 μg/mL. However, when the same experiments are performed using 30 μM arachidonic acid, Salicylic acid is an ineffective inhibitor of COX-2 activity, with an apparent IC50 value of more than 100 μg/mL, and achieves a maximal inhibition of less than 50%[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
In Vivo |
In C57Bl/6 DIO mice, Salicylic acid decreases both fasting and postprandial plasma glucose levels. Furthermore, there is a trend to reduce plasma triglyceride levels after Salicylic acid treatment in C57Bl/6 DIO mice (P=0.059). Salicylic acid significantly reduces 11β-HSD1 mRNA in omental adipose tissue in C57Bl/6 DIO mice, with a similar trend in mesenteric adipose (P=0.057). In mesenteric adipose of C57Bl/6 DIO mice, Salicylic acid also reduces 11β-HSD1 enzyme activity[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
Clinical Trial |
|
||||||||||||
Molecular Weight |
138.12 |
||||||||||||
Formula |
C7H6O3 |
||||||||||||
CAS No. |
69-72-7 |
||||||||||||
Appearance |
Solid |
||||||||||||
Color |
Off-white to light brown |
||||||||||||
SMILES |
O=C(O)C1=CC=CC=C1O |
||||||||||||
Structure Classification |
|
||||||||||||
Initial Source |
|
||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere. |
||||||||||||
Storage |
4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
||||||||||||
Solvent & Solubility |
In Vitro:
DMSO : ≥ 50 mg/mL (362.00 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) H2O : 1 mg/mL (7.24 mM; Need ultrasonic) *"≥" means soluble, but saturation unknown. Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
The co-solvents required include: DMSO,
. All of co-solvents are available by MedChemExpress (MCE).
, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||
Purity & Documentation |
Purity: 98.42% |
||||||||||||
References |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
H2O / DMSO | 1 mM | 7.2401 mL | 36.2004 mL | 72.4008 mL | 181.0020 mL |
5 mM | 1.4480 mL | 7.2401 mL | 14.4802 mL | 36.2004 mL | |
DMSO | 10 mM | 0.7240 mL | 3.6200 mL | 7.2401 mL | 18.1002 mL |
15 mM | 0.4827 mL | 2.4134 mL | 4.8267 mL | 12.0668 mL | |
20 mM | 0.3620 mL | 1.8100 mL | 3.6200 mL | 9.0501 mL | |
25 mM | 0.2896 mL | 1.4480 mL | 2.8960 mL | 7.2401 mL | |
30 mM | 0.2413 mL | 1.2067 mL | 2.4134 mL | 6.0334 mL | |
40 mM | 0.1810 mL | 0.9050 mL | 1.8100 mL | 4.5251 mL | |
50 mM | 0.1448 mL | 0.7240 mL | 1.4480 mL | 3.6200 mL | |
60 mM | 0.1207 mL | 0.6033 mL | 1.2067 mL | 3.0167 mL | |
80 mM | 0.0905 mL | 0.4525 mL | 0.9050 mL | 2.2625 mL | |
100 mM | 0.0724 mL | 0.3620 mL | 0.7240 mL | 1.8100 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Salicylic acid Related Classifications
- Inflammation/Immunology Cancer
- Cancer Targeted Therapy Cancer Immunotherapy Cancer Metabolism and Metastasis
- Immunology/Inflammation Autophagy Apoptosis Metabolic Enzyme/Protease
- COX Autophagy Mitophagy Apoptosis Endogenous Metabolite